SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Phase 2 POTS data positive

Regeneron Pharmaceuticals, Inc. · PRESS-RELEASE filed Nov 12, 2026 at 17:00 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Nov 12, 2026 at 17:00 ET

Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart in POTS, showing a single 450 mg dose reduced heart rate upon standing and improved symptoms through four weeks. A potentially pivotal Phase 3 trial is planned for the first half of 2027. No FDA-approved treatments currently exist for POTS, which affects 500,000 to several million people in the U.S.

  • Phase 2 PINNACLE trial evaluated single subcutaneous doses of baloncibart 150 mg (n=27) or 450 mg (n=28) vs placebo (n=27) in POTS patients.
  • Baloncibart 450 mg reduced DeltaHR vs placebo at day 8 with LS mean difference of -11.4 bpm (nominal p=0.0007) and at day 29 with -7.4 bpm (nominal p=0.0124).
  • Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living vs placebo at day 29 per LWPQ.
  • No FDA-approved treatments exist for POTS; potentially pivotal Phase 3 trial planned for first half of 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access